123 related articles for article (PubMed ID: 22359194)
1. The thrombin inhibitor, argatroban, inhibits breast cancer metastasis to bone.
Asanuma K; Wakabayashi H; Okamoto T; Asanuma Y; Akita N; Yoshikawa T; Hayashi T; Matsumine A; Uchida A; Sudo A
Breast Cancer; 2013 Jul; 20(3):241-6. PubMed ID: 22359194
[TBL] [Abstract][Full Text] [Related]
2. Thrombin inhibitor, argatroban, prevents tumor cell migration and bone metastasis.
Asanuma K; Wakabayashi H; Hayashi T; Okuyama N; Seto M; Matsumine A; Kusuzaki K; Suzuki K; Uchida A
Oncology; 2004; 67(2):166-73. PubMed ID: 15539922
[TBL] [Abstract][Full Text] [Related]
3. Argatroban more effectively inhibits the thrombin activity in synovial fluid than naturally occurring thrombin inhibitors.
Asanuma K; Yoshikawa T; Yoshida K; Okamoto T; Asanuma Y; Hayashi T; Akita N; Oi T; Nishimura A; Hasegawa M; Sudo A
Cell Mol Biol (Noisy-le-grand); 2016 May; 62(6):27-32. PubMed ID: 27262798
[TBL] [Abstract][Full Text] [Related]
4. The thrombin inhibitor Argatroban reduces breast cancer malignancy and metastasis via osteopontin-dependent and osteopontin-independent mechanisms.
Schulze EB; Hedley BD; Goodale D; Postenka CO; Al-Katib W; Tuck AB; Chambers AF; Allan AL
Breast Cancer Res Treat; 2008 Nov; 112(2):243-54. PubMed ID: 18097747
[TBL] [Abstract][Full Text] [Related]
5. Thrombin inhibitor argatroban modulates bone marrow stromal cells behaviors and promotes osteogenesis through canonical Wnt signaling.
Song J; Jiang N; Gan X; Zhi W; Zhu Z
Life Sci; 2021 Mar; 269():119073. PubMed ID: 33460666
[TBL] [Abstract][Full Text] [Related]
6. Argatroban and inhibition of the vasomotor actions of thrombin.
Winn MJ; Jain K; Ku DD
J Cardiovasc Pharmacol; 1993 Nov; 22(5):754-60. PubMed ID: 7506329
[TBL] [Abstract][Full Text] [Related]
7. Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin.
Wong PC; Jiang X
Thromb Haemost; 2010 Aug; 104(2):302-10. PubMed ID: 20589316
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of thrombin-induced vascular endothelial growth factor production in human neuroblastoma (NB-1) cells by argatroban.
Sarker KP; Biswas KK; Yamaji K; Yamakuchi M; Hashiguchi T; Lee KY; Maruyama I
Pathophysiol Haemost Thromb; 2005; 34(1):41-7. PubMed ID: 16293985
[TBL] [Abstract][Full Text] [Related]
9. [Experimental and clinical results with the thrombin inhibitor Argatroban].
Breddin HK
Hamostaseologie; 2002 Aug; 22(3):55-9. PubMed ID: 12215762
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of factor Xa-induced platelet aggregation by a selective thrombin inhibitor, argatroban.
Kawai H; Yamamoto T; Hara H; Tamao Y
Thromb Res; 1994 May; 74(3):185-91. PubMed ID: 8042187
[TBL] [Abstract][Full Text] [Related]
11. Platelet activity, coagulation, and fibrinolysis during exercise in healthy males: effects of thrombin inhibition by argatroban and enoxaparin.
Li N; He S; Blombäck M; Hjemdahl P
Arterioscler Thromb Vasc Biol; 2007 Feb; 27(2):407-13. PubMed ID: 17138937
[TBL] [Abstract][Full Text] [Related]
12. Effects of argatroban on thrombin-induced events in cultured vascular smooth muscle cells.
Hijikata-Okunomiya A; Nakaya Y; Inoue N; Takahashi A; Taniguchi T; Wanaka K; Tsuda Y; Okada Y; Ishikawa Y
Thromb Res; 2000 Feb; 97(4):257-62. PubMed ID: 10674413
[No Abstract] [Full Text] [Related]
13. Combined administration of aspirin and a specific thrombin inhibitor in man.
Clarke RJ; Mayo G; FitzGerald GA; Fitzgerald DJ
Circulation; 1991 May; 83(5):1510-8. PubMed ID: 2022012
[TBL] [Abstract][Full Text] [Related]
14. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant Hirudin.
Berry CN; Girardot C; Lecoffre C; Lunven C
Thromb Haemost; 1994 Sep; 72(3):381-6. PubMed ID: 7855788
[TBL] [Abstract][Full Text] [Related]
15. Aptamer-Based Enzyme Capture Assay for Measurement of Plasma Thrombin Levels.
Müller J; Becher T; Mayer G; Pötzsch B
Methods Mol Biol; 2016; 1380():179-89. PubMed ID: 26552826
[TBL] [Abstract][Full Text] [Related]
16. Small-molecule direct antithrombins: argatroban.
Fareed J; Jeske WP
Best Pract Res Clin Haematol; 2004 Mar; 17(1):127-38. PubMed ID: 15171962
[TBL] [Abstract][Full Text] [Related]
17. Pharmacology of argatroban.
Jeske WP; Fareed J; Hoppensteadt DA; Lewis B; Walenga JM
Expert Rev Hematol; 2010 Oct; 3(5):527-39. PubMed ID: 21083469
[TBL] [Abstract][Full Text] [Related]
18. The thrombin inhibitor argatroban does not influence the endothelium-dependent relaxant and contractile responses of isolated rabbit carotid arteries.
Schrödter HM; Glusa E
Exp Toxicol Pathol; 2003 Jun; 54(5-6):499-504. PubMed ID: 12877364
[TBL] [Abstract][Full Text] [Related]
19. Activity of a sub-cutaneously administered novel mixed micellar formulation of argatroban in rat and rabbit models of venous thrombosis.
Berry CN; Visconte C; Lecoffre C; Lochot S; Girard D
Thromb Haemost; 2000 Aug; 84(2):286-90. PubMed ID: 10959702
[TBL] [Abstract][Full Text] [Related]
20. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation.
Warkentin TE; Greinacher A; Craven S; Dewar L; Sheppard JA; Ofosu FA
Thromb Haemost; 2005 Nov; 94(5):958-64. PubMed ID: 16363236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
